dave@edgewoodonc.com
BTX-A51 is a multi-kinase inhibitor targeting CK1α, CDK7, and CDK9 to induce cancer cell apoptosis.

Edgewood Oncology is a clinical-stage biotechnology company advancing BTX-A51 for hematologic malignancies and genetically-defined solid tumors.
edgewoodoncology.comCrawled Nov 2, 2026
BTX-A51 is a multi-kinase inhibitor targeting CK1α, CDK7, and CDK9 to induce cancer cell apoptosis.
Edgewood Oncology’s pipeline includes BTX-A51 for hematologic malignancies and genetically-defined solid tumors, such as AML and GATA3-mutant breast cancer.
BROOKLINE, Mass.—October 6, 2024--Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, today announced that the first patient has been dosed in a Phase 1 investigator-sponsored study of
BROOKLINE, Mass.--(BUSINESSWIRE)--May 21, 2024--Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, today announced that the first two patients with metastatic breast cancer were
BROOKLINE, Mass.--(BUSINESSWIRE)—April 28, 2025--Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, today announced the presentation of new preclinical data presented by Dana-Farber C
Data published today by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School to be presented at the American Association of Cancer Research (AACR) Annual Meeting 2024 BROOKLINE, Mass.--(BUSINESSWIRE)--April 7, 2024--Edgewood Oncology, a clinical-stage biotechnology company
BROOKLINE, Mass—April 16, 2025--Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, today announced the upcoming presentation of new preclinical data from studies of BTX-A51 in human l
Dan Janney, Edgewood Oncology Board of Directors, brings nearly 25 years of experience in life sciences investing, leading the funding of 35 companies.
David N. Cook, Ph.D., CEO at Edgewood Oncology, brings 30 years of biotech leadership, driving successful IPOs, acquisitions, and product commercialization.
Meet Isan Chen, MD, Board of Directors at Edgewood Oncology. With over 20 years in oncology, he leads groundbreaking clinical trials.
Meet Prof. Yinon Ben-Neriah, M.D., Ph.D., Scientific Founder at Edgwood Oncology and a leading expert in Immunology and Cancer Research at Hebrew University.
Zung Thai, M.D., Ph.D., Chief Medical Officer at Edgewood Oncology, boasts 18 years of oncology leadership, driving clinical and regulatory initiatives
Edgewood Oncology develops BTX-A51, a treatment for challenging cancers.
Edgewood Oncology was founded to advance BTX-A51, which showed synergistic anti-tumor effects and safety in Phase 1 trials for AML and solid tumors.
Edgewood Oncology was founded to advance BTX-A51, which showed synergistic anti-tumor effects and safety in Phase 1 trials for AML and solid tumors.
Edgewood Oncology’s Privacy Policy describes how it collects, uses, and protects user information.
Edgewood Oncology’s Terms of Service outline user rights and responsibilities for its services.
Edgewood Oncology begins dosing the first two patients in a Phase IIa clinical trial for **BTX-A51**, a potential therapy targeting **GATA3 mutations** in metastatic breast cancer. The study explores BTX-A51’s efficacy in patients whose tumors carry these mutations, which occur in about **15% of breast cancer cases**. The trial marks a key step in evaluating the drug’s safety and potential as a precision oncology treatment.
Edgewood Oncology treats the first two patients with metastatic breast cancer using BTX-A51, a multi-specific kinase inhibitor targeting CK1α, CDK7, and CDK9. The Phase 2a study focuses on genetically-defined solid tumors. The drug aims to synergistically disrupt key cancer regulators in patients with advanced disease.
Edgewood Oncology reports positive efficacy results for its drug candidate **BTX-A51** in preclinical liposarcoma models. The findings, published by **Dana-Farber Cancer Institute** and **Hebrew University-Hadassah Medical School**, will be presented at the **AACR Annual Meeting 2024**. The study evaluates BTX-A51’s potential as a targeted therapy for this rare cancer type.
Edgewood Oncology raises $20 million in Series A funding to advance clinical trials for its lead cancer therapy, BTX-A51. The company, based in Massachusetts, focuses on developing novel oncology treatments. The investment supports further research and testing of the therapy in patients.
Edgewood Oncology secures **$20 million in Series A funding** to develop **BTX-A51**, a novel small-molecule multi-kinase inhibitor targeting hematologic malignancies and genetically defined solid tumors. The therapy aims to synergistically co-target master regulators of cancer to induce cancer cell death. Clinical advancement focuses on precision oncology approaches for genetically characterized tumors.